Crofelemer

About Jaguar Health

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

About Jaguar Health

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

About Jaguar Health

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

Therapeutic Areas